About immuron - IMRN
Immuron Ltd. is a biopharmaceutical company, which focuses on the development and commercialization of a novel class of specifically targeted polyclonal antibodies. It operates through the Hyper-immune Products and Research and Development (R&D) segments. The Hyper-immune Products segment includes income and expenses directly attributable to Travelan and Protectyn activities. The Research and Development segment refers to the group’s R&D projects performed in Australia and United States. The company was founded on January 13, 1994, and is headquartered in Blackburn, Australia.
IMRN At a Glance
Immuron Ltd.
25-37 Chapman Street
Blackburn, Victoria (VIC) 3131
| Phone | 61-3-8892-4802 | Revenue | 4.72M | |
| Industry | Pharmaceuticals: Major | Net Income | -3,378,034.82 | |
| Sector | Health Technology | 2025 Sales Growth | 46.891% | |
| Fiscal Year-end | 06 / 2026 | Employees | N/A | |
| View SEC Filings |
IMRN Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 2.129 |
| Price to Book Ratio | 1.925 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.425 |
| Enterprise Value to Sales | 1.314 |
| Total Debt to Enterprise Value | N/A |
IMRN Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | N/A |
| Receivables Turnover | 3.74 |
| Total Asset Turnover | 0.554 |
IMRN Liquidity
| Current Ratio | 5.094 |
| Quick Ratio | 4.192 |
| Cash Ratio | 2.984 |
IMRN Profitability
| Gross Margin | 64.71 |
| Operating Margin | -92.881 |
| Pretax Margin | -86.82 |
| Net Margin | -71.579 |
| Return on Assets | -39.686 |
| Return on Equity | -49.042 |
| Return on Total Capital | -63.88 |
| Return on Invested Capital | -48.728 |
IMRN Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |